Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
0.455
+0.014 (3.20%)
At close: Mar 9, 2026, 4:00 PM EDT
0.446
-0.009 (-2.00%)
After-hours: Mar 9, 2026, 6:25 PM EDT
Nexalin Technology Employees
Nexalin Technology had 6 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$26,155
Profits / Employee
-$1,446,485
Market Cap
8.49M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6 | 0 | - |
| Dec 31, 2023 | 6 | 0 | - |
| Dec 31, 2022 | 6 | -4 | -40.00% |
| Dec 31, 2021 | 10 | 6 | 150.00% |
| Dec 31, 2020 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Trinity Biotech | 401 |
| Lifeward | 80 |
| Beyond Air | 61 |
| Intelligent Bio Solutions | 55 |
| Biomerica | 54 |
| enVVeno Medical | 37 |
| Tenon Medical | 27 |
| Sintx Technologies | 20 |
NXL News
- 13 days ago - Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market - GlobeNewsWire
- 14 days ago - Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders - GlobeNewsWire
- 4 weeks ago - Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care - GlobeNewsWire
- 5 weeks ago - Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation - GlobeNewsWire
- 7 weeks ago - Published Peer-Reviewed Study Demonstrates Nexalin's DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD - GlobeNewsWire
- 3 months ago - Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer's Disease Program - GlobeNewsWire
- 3 months ago - Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4 - GlobeNewsWire
- 3 months ago - Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity - GlobeNewsWire